格隆汇2月12日丨慧源同创科技(01116.HK)宣布，董事会会议将于2026年2月27日(星期五)举行，藉以(其 中包括)知悉公司及其附属公司截至2025年12月31日止六个月之未经审核综合财务报表的情况。 ...

格隆汇2月12日丨美亨实业(01897.HK)公告，2月12日耗资3.5万港元回购7万股。 ...

格隆汇2月12日丨通达集团(00698.HK)公告，于2025年12月30日及2026年2月12日，公司间接非全资附属 公司通达创智(厦门)及通达创智(石狮)利用其闲置资金认购若干理财产品，包括认购(i)第一项兴业银行 理财产品、第二项兴业银行理财产品、第三项兴业银行理财产品及第四项兴业银行理财产品，认购金额 分别为人民币1400万元、人民币1800万元、人民币4500万元及人民币1700万元。 ...

格隆汇2月12日丨三美股份(603379.SH)公布，信息披露义务人胡荣达先生于2026年2月12日通过集中竞 价交易及大宗交易方式累计减持公司股份365.93万股，占公司总股本的0.60%。本次减持后，胡荣达先 生及其一致行动人合计持有公司股份的比例由60.60%减少至60.00%，权益变动触及5%刻度。 ...

Core Viewpoint - Company subsidiaries participated in the national organized procurement for the continuation of drug agreements, with 11 products selected for procurement, indicating a stable revenue stream for the company in the coming years [1][2] Group 1: Procurement Details - The company’s subsidiaries, Hangzhou Kang En Bei Pharmaceutical Co., Ltd. and Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., submitted applications for the national organized procurement continuation [1] - The selected drugs include sustained-release capsules of Tamsulosin Hydrochloride, injectable Piperacillin Sodium and Tazobactam Sodium, and enteric-coated Pantoprazole Sodium tablets among others [1][2] - The expected sales revenue from the selected drugs for 2024 is approximately 385.29 million yuan, accounting for 5.91% of the company's total revenue for that year [1] Group 2: Financial Impact - For the first three quarters of 2025, the total expected sales revenue from the selected drugs is about 296.15 million yuan, representing 5.95% of the company's revenue for that period [1] - The procurement results are expected to be implemented by the end of March 2026, with medical institutions prioritizing the use of selected drugs [2] - The prices of the selected drugs are expected to remain stable or decrease, with procurement quotes maintaining stability compared to the average sales prices in 2025 [2]

本溪子公司申报的流感病毒裂解疫苗（高剂量），系用世界卫生组织（WHO）推荐的甲型和乙型流行 性感冒病毒株分别接种鸡胚，经培养、收获病毒液、纯化、病毒裂解、灭活后制成，有效成分是常规剂 量流感的四倍。 格隆汇2月12日丨成大生物(688739.SH)公布，公司全资子公司成大生物（本溪）有限公司（以下简 称"本溪子公司"）于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》（通知书编 号：2026LP00405），批准流感病毒裂解疫苗（高剂量）开展临床试验。 ...

▲大众点评定年夜饭、支付定金、免责取消示例 通过一系列线上产品改造和数字化升级，美团将传统年夜饭"电话留位、口头约定"的模糊契约模式，改 造为权责清晰、双向保障的交易闭环模式，让预订服务更具确定性。无论是消费者担心预订后无法接 待，还是商家关注的临时取消带来餐位闲置，通过升级后的预订服务，双方的困扰都有望得到改善。 春节临近，年夜饭预订进入高峰。日前，美团升级年夜饭预订服务保障，引入年夜饭预订定金系统"锁 餐位"，VR实景技术"选包间"，把传统的年夜饭预订从"意向登记"升级为"确定性交易"，帮消费者解 决"预订后不接待""到店无座"等困扰。 新模式下，消费者在美团预订年夜饭时，支付定金即完成餐位锁定。若商家无法履约，该商家需向用户 双倍返还定金。 针对消费者可能因行程变动需要取消预订的情况，产品也提供了缓冲空间。比如，商家可自主设置"免 责取消时间"，在此期限前，如果消费者取消预订，定金将全额自动退还；超时后，则需与商家协商确 认。 以"徐记海鲜·MASTER大师店（侨城一号店）"为例，该店已全面接入美团包间VR展示与春节定金系 统，门店负责人表示，规则上线后消费者下单决策更果断更放心，除夕包间目前已基本订满 ...

格隆汇2月12日丨陕西黑猫(601015.SH)在投资者互动平台表示，阳霞矿业尚处于建设中，并未投产。 ...

Core Insights - The company has established a strong competitive moat in technology, licensing, mass production capabilities, and operational capacity, with significant advancements in autonomous driving technology and regulatory approvals [1][2] Group 1: Technology and Innovation - The company has developed a universal technology platform called WeRide One, which integrates AI models, software algorithms, modular hardware design, and cloud architecture, showcasing high versatility and scalability [1] - The recent launch of WeRide GENESIS has significantly enhanced the company's autonomous driving algorithms' ability to handle complex real-world scenarios, improving iteration efficiency and reducing the time and cost of traditional road testing [1] Group 2: Licensing and Regulatory Approvals - The company has achieved a first-mover advantage in licensing, having obtained autonomous driving licenses in eight countries, including China, UAE, Singapore, France, the USA, Saudi Arabia, Belgium, and Switzerland, by 2025 [1] Group 3: Fleet and Operational Capacity - As of January 12, 2026, the company's global Robotaxi fleet has reached 1,023 vehicles, with approximately 200 units deployed in the Middle East, aiming for tens of thousands of Robotaxis by 2030 [1] - The company is actively expanding its presence in the domestic Robotaxi market, with operations in major cities like Beijing, Guangzhou, and Shanghai, and plans to introduce autonomous taxi services in Shanghai by July 2025 [2] Group 4: Global Expansion Strategy - The company has a robust global expansion strategy, with plans to increase its Robotaxi fleet in the Middle East from 200 to 500-1,000 vehicles by 2026, and is set to launch a fully autonomous commercial operation in Abu Dhabi with Uber by November 26, 2025 [2] Group 5: Market Position and Future Prospects - The company employs a platform strategy in its L4 business, leveraging its success in autonomous taxi development to explore other autonomous vehicle solutions, including minibuses and freight vehicles [2] - By August 2025, the company is projected to hold a 36% market share in the global autonomous minibus market, ranking first based on revenue [2] Group 6: Financial Projections - The company forecasts net losses of 1.69 billion yuan, 1.37 billion yuan, and 1.10 billion yuan for the years 2025 to 2027, with corresponding EPS of -1.65 yuan, -1.33 yuan, and -1.07 yuan [3]

格隆汇2月12日丨亿仕登控股(01656.HK)宣布，公司谨订于2026年2月27日(星期五)举行董事会会议，藉 以(其中包括)考虑及批准公司及其附属公司截至2025年12月31日止年度之未经审核综合财务业绩以供发 布及考虑建议派发末期股息(如有)。 ...